Cargando…

Toxicity Profile of Chimeric Antigen Receptor T-Cell and Bispecific Antibody Therapies in Multiple Myeloma: Pathogenesis, Prevention and Management

Multiple myeloma is the second-most common hematologic malignancy in adults worldwide. Despite ongoing advancement in therapeutic modalities, it remains an incurable disease with a 5-year survival rate of approximately 50%. The recent development and introduction of anti-BCMA immunotherapies into cl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Markouli, Mariam, Ullah, Fauzia, Unlu, Serhan, Omar, Najiullah, Lopetegui-Lia, Nerea, Duco, Marissa, Anwer, Faiz, Raza, Shahzad, Dima, Danai
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10378049/ https://www.ncbi.nlm.nih.gov/pubmed/37504327 http://dx.doi.org/10.3390/curroncol30070467

Ejemplares similares

Recent Advances in Adult Post-Transplant Lymphoproliferative Disorder
por: Markouli, Mariam, et al.
Publicado: (2022)

Management of Relapsed–Refractory Multiple Myeloma in the Era of Advanced Therapies: Evidence-Based Recommendations for Routine Clinical Practice
por: Dima, Danai, et al.
Publicado: (2023)

Advances in the treatment of Hodgkin lymphoma: Current and future approaches
por: Ullah, Fauzia, et al.
Publicado: (2023)

Early-Onset Colorectal Cancer: Current Insights
por: Ullah, Fauzia, et al.
Publicado: (2023)

Emerging Role of Antibody-Drug Conjugates and Bispecific Antibodies for the Treatment of Multiple Myeloma
por: Tai, Waqqas, et al.
Publicado: (2022)

The Role of Bispecific Antibodies in Relapsed Refractory Multiple Myeloma: A Systematic Review
por: Khanam, Razwana, et al.
Publicado: (2023)

Bispecific Chimeric Antigen Receptor T Cell Therapy for B Cell Malignancies and Multiple Myeloma
por: Cronk, Robert J., et al.
Publicado: (2020)

Multiple Myeloma Therapy: Emerging Trends and Challenges
por: Dima, Danai, et al.
Publicado: (2022)

Geographic and Racial Disparities in Access to Chimeric Antigen Receptor–T Cells and Bispecific Antibodies Trials for Multiple Myeloma
por: Alqazaqi, Raghad, et al.
Publicado: (2022)

Precision Oncology Targets in Biliary Tract Cancer
por: Farha, Nicole, et al.
Publicado: (2023)

Fallopian tube cancer– challenging to diagnose but not as infrequent as originally thought
por: Hundal, Jasmin, et al.
Publicado: (2021)

Discovery, Significance, and Utility of JAK2 Mutation in Squamous Cell Carcinoma of the Lung
por: Hundal, Jasmin, et al.
Publicado: (2022)

Risk of Venous Thromboembolism in Multiple Myeloma Patients During the Immediate Peri-Autologous Hematopoietic Cell Transplantation Phase
por: Awada, Hussein, et al.
Publicado: (2023)

Still's Disease and Myopericarditis
por: Kumar, Manish, et al.
Publicado: (2019)

Monoclonal and Bispecific Anti-BCMA Antibodies in Multiple Myeloma
por: Dalla Palma, Benedetta, et al.
Publicado: (2020)

Bispecific antibodies for non-Hodgkin’s lymphomas and multiple myeloma
por: Castaneda-Puglianini, Omar, et al.
Publicado: (2021)

Hyperprogression in PDL1 Expressive, Recurrent Gastroesophageal-junction Adenocarcinoma After Pembrolizumab
por: Sama, Shashank, et al.
Publicado: (2019)

TanCAR: A Novel Bispecific Chimeric Antigen Receptor for Cancer Immunotherapy
por: Grada, Zakaria, et al.
Publicado: (2013)

Bispecific T-Cell Engagers and Chimeric Antigen Receptor T-Cell Therapies in Glioblastoma: An Update
por: Alsajjan, Roa, et al.
Publicado: (2023)

Targeting multiple myeloma with nanobody-based heavy chain antibodies, bispecific killer cell engagers, chimeric antigen receptors, and nanobody-displaying AAV vectors
por: Hambach, Julia, et al.
Publicado: (2022)

Management of Adverse Reactions for BCMA-Directed Therapy in Relapsed Multiple Myeloma: A Focused Review
por: Khanam, Razwana, et al.
Publicado: (2023)

Autoimmune Diseases and Rosai-Dorfman Disease Coexist More Commonly than Expected: Two Case Reports
por: Lopetegui-Lia, Nerea, et al.
Publicado: (2019)

Streptococcus viridans Endocarditis Affecting All Four Valves
por: Kumar, Manish, et al.
Publicado: (2019)

A Case of Immunotherapy-Induced Colitis Complicated by Perforation and Treated with Infliximab Postoperatively
por: Delasos, Lukas, et al.
Publicado: (2019)

A Migraneur with a Usual Headache: A Near-miss of Cerebral Venous Thrombosis
por: Asad, Syed Daniyal, et al.
Publicado: (2019)

Bile Cast Nephropathy Secondary to Hemophagocytic Lymphohistiocytosis With Liver Failure
por: Chango Azanza, Juan Jose, et al.
Publicado: (2020)

Breast Cancer Metastasis Masquerading as Primary Colon and Gastric Cancer: A Case Report
por: Noor, Arish, et al.
Publicado: (2020)

Bispecific Antibodies: A New Era of Treatment for Multiple Myeloma
por: Zhou, Xiang, et al.
Publicado: (2020)

Bispecific T Cell Engagers for the Treatment of Multiple Myeloma: Achievements and Challenges
por: Alhallak, Kinan, et al.
Publicado: (2021)

Bispecific antibodies in multiple myeloma treatment: A journey in progress
por: Cho, Shih-Feng, et al.
Publicado: (2022)

Infectious complications of bispecific antibody therapy in patients with multiple myeloma
por: Sim, Beatrice Z., et al.
Publicado: (2023)

Evaluating Daratumumab in the Treatment of Multiple Myeloma: Safety, Efficacy and Place in Therapy
por: Dima, Danai, et al.
Publicado: (2020)

Oncolytic Viruses for Multiple Myeloma Therapy
por: Calton, Christine M., et al.
Publicado: (2018)

Acute Myopericarditis with Crohn's Disease Flare-up
por: Kumar, Manish, et al.
Publicado: (2019)

Primary central nervous system marginal zone B‐cell lymphoma arising from the dural meninges: A case report and review of literature
por: Lopetegui‐Lia, Nerea, et al.
Publicado: (2020)

Extrapyramidal Symptoms with Administration of Lenalidomide Maintenance Therapy for Multiple Myeloma
por: Sagar, FNU, et al.
Publicado: (2018)

T-cell redirecting bispecific antibodies targeting BCMA for the treatment of multiple myeloma
por: Verkleij, Christie P.M., et al.
Publicado: (2020)

A Focus on CAR T-Cell Therapy and Bispecific Antibodies in Multiple Myeloma
por: Catamero, Donna, et al.
Publicado: (2022)

Bispecific Antibodies in Multiple Myeloma: Opportunities to Enhance Efficacy and Improve Safety
por: Swan, Dawn, et al.
Publicado: (2023)

T-cell redirecting bispecific and trispecific antibodies in multiple myeloma beyond BCMA
por: van de Donk, Niels W.C.J., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_bu1kc4gr7fdbi7njo7hnvtvkim